The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy.
Dapagliflozin
Diabetic nephropathy
Renal function
Sodium-glucose cotransport protein 2 inhibitor
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
06
02
2022
accepted:
11
03
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
To investigate the clinical efficacy and safety of dapagliflozin in the treatment of diabetic nephropathy (DN). A total of 120 DN patients admitted to our hospital from June 2017 to March 2020 were divided into control and experimental groups, with 60 cases in each group. The control group received valsartan, and the experimental group received dapagliflozin for 3 months. Body mass index (BMI), hemoglobin A1c (HbA1c), serum creatinine (sCr), uric acid (UA), urine microalbumin (uMA), urine creatinine (uCr), and bilateral kidney function were compared before and after treatment, and adverse reactions in both groups were observed. Serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were also evaluated. After treatment, except for BMI in the control group, all indexes in both groups were significantly improved. The BMI, HbA1c, sCr, UA, and uMA/uCr ratios of the experimental group were lower than those of the control group. Serum albumin (sAlb) levels were increased in both groups, and the experimental group showed a significant difference compared with the control group. Estimated glomerular filtration rate (eGFR) levels were increased in both groups, and the experimental group was higher than the control group, with no significant differences. Serum IL-6 and TNF-α levels in both groups were lower, and the experimental group was significantly lower than the control group. No serious adverse reactions were observed in either group. The efficacy of dapagliflozin was demonstrated by its ability to improve diabetes, prevent nephropathy exacerbation, and reduce symptomatic reactions. The low rate of adverse reactions makes dapagliflozin a very safe medication.
Identifiants
pubmed: 35351189
doi: 10.1186/s13098-022-00815-y
pii: 10.1186/s13098-022-00815-y
pmc: PMC8966174
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Cardiovasc Drugs Ther. 2021 Jul 7;:
pubmed: 34232433
Circulation. 2020 Feb 25;141(8):704-707
pubmed: 31707794
Front Physiol. 2021 May 05;12:649587
pubmed: 34025445
J Clin Invest. 2007 Apr;117(4):1068-77
pubmed: 17404621
Life Sci. 2021 Sep 1;280:119018
pubmed: 33549594
N Engl J Med. 2009 Nov 19;361(21):2019-32
pubmed: 19880844
Clin Pharmacol Ther. 2009 May;85(5):513-9
pubmed: 19129749
Biomed Pharmacother. 2019 Jan;109:910-920
pubmed: 30551545
Curr Opin Nephrol Hypertens. 2017 Sep;26(5):345-350
pubmed: 28538016
J Cell Mol Med. 2018 Jan;22(1):302-314
pubmed: 28857467
Eur J Clin Invest. 2005 Dec;35 Suppl 3:13-9
pubmed: 16281953
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Biochem Biophys Res Commun. 2001 Nov 9;288(4):849-54
pubmed: 11688986
Nephrol Dial Transplant. 2008 Apr;23(4):1166-72
pubmed: 17967803
Kidney Int. 2010 Feb;77(4):312-8
pubmed: 20016470
Cell Metab. 2005 Jun;1(6):409-14
pubmed: 16054090
Diabetes. 1989 Jan;38(1):75-83
pubmed: 2909415
Kidney Int. 2020 Jan;97(1):202-212
pubmed: 31791665
J Diabetes Metab Disord. 2017 Dec 19;16:47
pubmed: 29270392
Front Cell Dev Biol. 2015 Jul 21;3:42
pubmed: 26258123
Nat Rev Nephrol. 2020 May;16(5):269-288
pubmed: 32060481
Cell Metab. 2014 Nov 4;20(5):882-897
pubmed: 25440060
Biomol Ther (Seoul). 2021 Jul 1;29(4):365-372
pubmed: 33888647
Am J Physiol Endocrinol Metab. 2011 Feb;300(2):E287-95
pubmed: 20959534
J Pharmacol Exp Ther. 2019 Dec;371(3):675-683
pubmed: 31585986